{
    "pmcid": "11289243",
    "qa_pairs": {
        "What is a key consideration for designing nanobodies against the JN.1 variant?": [
            "Targeting conserved regions or multiple epitopes",
            "Focusing solely on the N-terminal domain",
            "Avoiding the receptor-binding domain",
            "Designing for single epitope specificity"
        ],
        "What percentage of patients required hospitalization due to the JN.1 variant?": [
            "45%",
            "30%",
            "55%",
            "65%"
        ],
        "What was the prevalence of the JN.1 variant in Tamil Nadu, India by December 2023?": [
            "95% incidence",
            "80% incidence",
            "70% incidence",
            "60% incidence"
        ],
        "Which comorbidity was present in over 50% of patients affected by the JN.1 variant?": [
            "Diabetes mellitus",
            "Hypertension",
            "Asthma",
            "Chronic kidney disease"
        ],
        "Which mutation is identified as a universal mutation known for immune evasion in the JN.1 variant?": [
            "N501Y",
            "D614G",
            "E484K",
            "L452R"
        ]
    }
}